Clinical TrialsSearch results
Number of results: 2560
Completed
- A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19
- COVID-19
- Hibi Kazushige
- 2024-03-28
Other
- A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
- Glioblastoma, Adult-type Diffuse Gliomas
- Ueda Eiji
- 2022-09-28
Completed
- A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
- Hyperphosphatemia
- Mita Seiji
- 2023-01-22
Other
- A Phase 2/3 Study of S-268019 in Adults over 60 years of ages(COVID-19)
- Prevention of COVID-19
- Nagata Tsutae
- 2022-07-26
Other
- A Phase 2/3 Study of S-268019 in Participants Aged 12 to 19 Years(COVID-19)
- Prevention of COVID-19
- Nagata Tsutae
- 2022-05-17
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to an Alpha-Glucosidase Inhibitor
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01
Other
- A Phase 2/3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 5 to 11 Years Who Have Completed Initial Immunization with Comirnaty Intramuscular Injection (Univalent: Original Strain)
- Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)
- Inoguchi Akihiro
- 2023-02-28